Danaher Corporation (DHR)
| Market Cap | 170.94B |
| Revenue (ttm) | 29.57B |
| Net Income (ttm) | 5.87B |
| Shares Out | 738.93M |
| EPS (ttm) | 7.93 |
| PE Ratio | 29.17 |
| Forward PE | 30.57 |
| Dividend | $0.96 (0.42%) |
| Ex-Dividend Date | Dec 28, 2023 |
| Volume | 1,407,554 |
| Open | 232.64 |
| Previous Close | 233.13 |
| Day's Range | 230.91 - 233.85 |
| 52-Week Range | 182.09 - 247.62 |
| Beta | 0.86 |
| Analysts | Buy |
| Price Target | 259.00 (+11.96%) |
| Earnings Date | Jan 30, 2024 |
About DHR
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; mic... [Read more]
Financial Performance
In 2022, Danaher's revenue was $31.47 billion, an increase of 6.85% compared to the previous year's $29.45 billion. Earnings were $7.10 billion, an increase of 13.30%.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for DHR stock is "Buy." The 12-month stock price forecast is $259.0, which is an increase of 11.96% from the latest price.
News
Danaher Schedules Fourth Quarter 2023 Earnings Conference Call
WASHINGTON , Dec. 21, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2023 on Tuesday, January 30, 202...
Will Danaher Stock Rebound To Pre-Inflation Shock Highs Of $300?
Danaher stock (NYSE: DHR), a conglomerate with products in environmental, life sciences, and diagnostics fields, trades at $220 per share, about 2% below the level seen in March 2021. DHR stock was tr...
Danaher completes $5.7 billion acquisition of Abcam
Medical tools supplier Danaher said on Wednesday it has completed the $5.7 billion acquisition of Abcam , overcoming the initial opposition from the founder of the protein consumables maker.
Danaher Completes Acquisition of Abcam
WASHINGTON , Dec. 6, 2023 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher") announced today it has completed its acquisition of Abcam plc (NASDAQ:ABCM) ("Abcam"). The acquisition of Abcam for...
Danaher Announces Quarterly Dividend
WASHINGTON , Dec. 5, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.24 per share of its common st...
Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales
CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam plc (Nasdaq: ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, entered into a def...
Danaher to Present at Evercore ISI HealthCONx Conference
WASHINGTON , Nov. 21, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Evercore ISI HealthCONx Conf...
Abcam Acquisition by Danaher Has Received All Identified Clearances; Transaction Expected to Close on December 6, 2023
CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam today announced that all Identified Clearances required in connection with the acquisition of the company by Danaher have been obtained.
Abcam shareholders approve $5.7 billion Danaher deal
Abcam shareholders on Monday approved the proposal from Danaher Corp to acquire all outstanding shares of the company for $24 per share in cash.
Shareholders of Abcam Approve Proposed Acquisition by Danaher
CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Shareholders of Abcam approve proposed acquisition by Danaher.
Statement from Dr. Jonathan Milner on the suspension of the “Vote AGAINST” campaign
Statement from Dr. Jonathan Milner on the suspension of the “Vote AGAINST” campaign CAMBRIDGE, England, 1 November 2023 - Jonathan Milner, the founder and one of the largest investors in Abcam plc (“A...
Danaher appoints Christopher Riley to Executive Vice President for Biotechnology
WASHINGTON , Oct. 31, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a leading global life sciences and diagnostics innovator, today announced that Christopher Rile...
Danaher Tops Earnings and Revenue Estimates. The Stock Is Rising.
Danaher posts third-quarter earnings of $2.02 a share on revenue of $6.87 billion.
The weight-loss drugs are coming for these companies — but here's why Coke, others, may be spared, says JPMorgan
Citing Vanda Research, the Wall Street Journal reports that the average individual-investor stock portfolio is up 150% since the start of 2014, versus around 140% for the S&P 500's SPX during the same...
Danaher Reports Third Quarter 2023 Results
WASHINGTON , Oct. 24, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the third quarter ended September 29, 2023. Net earnings refer to net earnings a...
Leading Independent Proxy Advisor Glass Lewis Joins ISS in Recommending Shareholders Vote “FOR” Danaher Corporation's Proposed Acquisition of Abcam
CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam announced that leading independent proxy advisor Glass Lewis recommended Abcam shareholders vote “FOR” Danaher's proposed acquisition of Abc...
Jonathan Milner Issues Statement Responding to the Glass Lewis Report
Jonathan Milner Issues Statement Responding to the Glass Lewis Report Welcomes the Glass Lewis report's observations on the disproportionate rewards for Abcam's Executive Directors and on the identifi...
Leading Proxy Advisor, ISS, Recommends Shareholders Vote “FOR” Danaher Corporation's Proposed Acquisition of Abcam
CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam announced that leading independent proxy advisor ISS recommended that Abcam shareholders vote “FOR” Danaher's proposed acquisition of Abcam.
Jonathan Milner Issues Statement Responding to ISS Report
Jonathan Milner Issues Statement Responding to ISS Report Urges shareholders to disregard the ISS report and continue to Vote AGAINST the current proposed acquisition of Abcam by Danaher CAMBRIDGE, En...
Jonathan Milner releases presentation to Abcam plc shareholders, outlining reasons to reject Danaher's bid and strategic vision for the Company
Jonathan Milner releases presentation to Abcam plc shareholders, outlining reasons to reject Danaher's bid and strategic vision for the Company
Independent Directors of Abcam Highlight Compelling Reasons for Shareholders to Support Proposed Sale to Danaher
CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam filed an investor presentation on the proposed sale of Abcam to Danaher and the Independent Directors mailed a letter to shareholders.
ABCAM INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Abcam plc - ABCM
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Abcam plc (Nasda...
Jonathan Milner issues Open Letter to shareholders of Abcam plc
Urges shareholders to question the scheme circular, the unacceptable Offer price and continue to Vote AGAINST the current proposed acquisition of Abcam by Danaher Corporation
Abcam Files and Mails Scheme Circular Seeking Approval of Acquisition of Abcam by Danaher for $24.00 per Share
CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam files and mails Scheme Circular seeking approval of acquisition of Abcam by Danaher for $24.00 per share.